Sandoz to distribute authorized Angiomax generic
This article was originally published in Scrip
Executive Summary
After having two patents invalidated by a federal appeals court last week for its top-selling anticoagulant Angiomax (bivalirudin), The Medicines Company has entered into a deal to let Novartis unit Sandoz distribute an "authorized" generic form of the drug in the US.